Recombinant Rat Mfge8 protein(23-427aa), His-tagged

• Cat.No.: Mfge8-669R
• Product Overview: Recombinant Rat Mfge8 protein(P70490)(23-427aa), fused with N-terminal His tag, was expressed in E.coli.

Specification

• Source: E.coli
• Species: Rat
• Tag: N-His
• Protein length: 23-427aa
• Form: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
• Molecular Mass: 51.1 kDa
• AASequence: ASGDFCDSSLCLNGGTCLMGQDNDI YCLCPEGFTGLVCNETEKGPCSPNP CFHDAKCLVTEDTQRGDIFTEYICQ CPVGYSGIHCELGCSTKLGLEGGAI ADSQISASSVYMGFMGLQRWGPELA RLYRTGIVNAWTASSYDSKPWIQVD FLRKMRVSGVMTQGASRAGRAEYLK TFKVAYSLDGRRFEFIQDESGTGDK EFMGNQDNNSLKINMFNPTLEAQYI RLYPVSCHRGCTLRFELLGCELHGC SEPLGLKNNTIPDSQITASSSYKTW NLRAFGWYPHLGRLDNQGKINAWTA QSNSAKEWLQVDLGTQKKVTGIITQ GARDFGHIQYVASYKVAHSDDGVQW TVYEEQGTSKVFQGNLDNNSHKKNI FEKPFMARYVRVLPLSWHNRITLRL ELLGC
• Purity: Greater than 90% as determined by SDS-PAGE.
• Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C.

Gene Information

• Gene Name: Mfge8 milk fat globule-EGF factor 8 protein [ Rattus norvegicus ]
• Official Symbol: Mfge8
• Synonyms: MFGE8; milk fat globule-EGF factor 8 protein; lactadherin; MFGM; SED1; MFG-E8; O-acetyl GD3 ganglioside synthase; O-acetyl disialoganglioside synthase; O-acetyltransferase milk fat globule membrane protein; O-acetyltransferase Milk fat glolbule membrane protein; AGS; MFGME8; OAcGD3S; MFGMP-E8
• Gene ID: 25277
• mRNA Refseq: NM_001040186
• Protein Refseq: NP_001035276

Reviews

08/08/2022

It has high application effect and safety in clinical treatment.

10/08/2021

MFGE8 has a high resolution in Western blots, which can distinguish similar protein molecular weights.

11/09/2020

Good stability and activity retention during long-term storage.

Q&As

Is there a relationship between MFGE8's structure and function?

The structure of MFGE8 determines its ability and stability to bind to other proteins. The study of its structure can help us understand its function and mechanism of action.

Does MFGE8 interact with other proteins?

MFGE8 can interact with a variety of other proteins, including Caspase-3, Caspase-8, EGFR, etc. These interactions enable it to regulate processes such as apoptosis, signal transduction, and cell adhesion.

What will future research on MFGE8 focus on?

Future studies of MFGE8 may focus on the following aspects: its structure-function relationship, mechanisms of interaction with other proteins, regulatory mechanisms in cells, and potential therapeutic applications. At the same time, the study of MFGE8's interaction with specific signal transduction pathways and its regulatory effect on cell growth and differentiation will also become one of the future research priorities.

What are the treatment strategies for MFGE8?

Therapeutic strategies for MFGE8 may include regulating its expression level, inhibiting its interaction with other proteins, and promoting or inhibiting its function. These methods may have potential applications in the treatment of cancer, neurodegenerative diseases, and autoimmune diseases.

Does MFGE8 have a role in neurodegenerative diseases?

In neurodegenerative diseases, MFGE8 may influence the survival and death processes of neurons by regulating apoptosis and signal transduction. It could be a potential target for the treatment of neurodegenerative diseases.

What factors should be considered in drug development for MFGE8?

Drug development against MFGE8 needs to consider its specificity, safety, pharmacokinetic properties, and potential side effects. In addition, issues such as the dosage form, route of administration and design of clinical trials need to be considered.